| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5546 | 2021 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2129* | 2021 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1389 | 2021 |
| Clinical features and management of human monkeypox: a retrospective observational study in the UK H Adler, S Gould, P Hine, LB Snell, W Wong, CF Houlihan, JC Osborne, ... The Lancet Infectious Diseases 22 (8), 1153-1162, 2022 | 1112 | 2022 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 798 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 760 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 704 | 2021 |
| Single-cell multi-omics analysis of the immune response in COVID-19 E Stephenson, G Reynolds, RA Botting, FJ Calero-Nieto, MD Morgan, ... Nature medicine 27 (5), 904-916, 2021 | 552 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021 | 457* | 2021 |
| First experience of COVID-19 screening of health-care workers in England E Hunter, DA Price, E Murphy, IS van der Loeff, KF Baker, D Lendrem, ... The Lancet 395 (10234), e77-e78, 2020 | 382 | 2020 |
| Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation KJ Ewer, GA O’Hara, CJA Duncan, KA Collins, SH Sheehy, ... Nature communications 4 (1), 2836, 2013 | 371 | 2013 |
| Preliminary assessment of the efficacy of a t-cell–based influenza vaccine, MVA-NP+ M1, in humans PJ Lillie, TK Berthoud, TJ Powell, T Lambe, C Mullarkey, AJ Spencer, ... Clinical infectious diseases 55 (1), 19-25, 2012 | 296 | 2012 |
| Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine RP Payne, S Longet, JA Austin, DT Skelly, W Dejnirattisai, S Adele, ... Cell 184 (23), 5699-5714. e11, 2021 | 290 | 2021 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 281 | 2021 |
| COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study JJ Manson, C Crooks, M Naja, A Ledlie, B Goulden, T Liddle, E Khan, ... The Lancet Rheumatology 2 (10), e594-e602, 2020 | 280 | 2020 |
| Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector GA O’Hara, CJA Duncan, KJ Ewer, KA Collins, SC Elias, FD Halstead, ... Journal of Infectious Diseases 205 (5), 772-781, 2012 | 265 | 2012 |
| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 256 | 2022 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 254 | 2012 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 399 (10320), 143, 2022 | 252 | 2022 |
| Novel coronavirus disease (Covid-19): the first two patients in the UK with person to person transmission PJ Lillie, A Samson, A Li, K Adams, R Capstick, GD Barlow, N Easom, ... Journal of Infection 80 (5), 578-606, 2020 | 245 | 2020 |
Matthias L SchmidConsultant Physician & Honorary Clinical Senior Lecturer of Infectious Diseases, University of NewcastleVerified email at ncl.ac.uk
